DGAP-News: Defence Therapeutics Inc.:  BREAKTHROUGH DISCOVERY: DEFENCE’S ACCUMTM VARIANT 'A1' CONVERTS MESENCHYMAL STROMAL CELLS INTO POTENT ANTIGEN PRESENTING CELLS SUITABLE FOR CANCER VACCINATION

With respect to cancer, the immune system relies on dendritic cells (DCs), a subset of potent endogenous APCs, to prime cytotoxic T lymphocytes (CTLs).